Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Conditions: Follicular Lymphoma Interventions: Drug: Mosunetuzumab; Drug: Lenalidomide; Drug: Rituximab; Drug: Obinutuzumab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristin; Drug: Prednisone; Drug: Rituximab; Drug: Obinutuzumab; Drug: Bendamustin Sponsors: The Lymphoma Academic Research Organisation; Lymphoma Study Association; Swiss Group for Clinical Cancer Research; Grupo Espa ñol de Linfomas y Transplante Autólogo de Médula Ósea Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis
Conditions: Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV Interventions: Drug: AB-101; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Rituximab Sponsors: Artiva Biotherapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Conditions: Mantle Cell Lymphoma Interventions: Drug: Rituximab; Drug: Pirtobrutinib Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Conditions: Severe Aplastic Anemia; Platelet Transfusion Refractoriness Interventions: Drug: Rituximab Sponsors: Institute of Hematology& Blood Diseases Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Conditions: B-cell Non-Hodgkin Lymphoma Interventions: Drug: Rocbrutinib; Biological: Rituximab; Drug: Cyclophosphamide; Drug: doxorubicin; Drug: Vincristin; Drug: Prednisone Sponsors: Guangzhou Lupeng Pharmaceutical Company LTD. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab; Procedure: Positron Emission Tomography; Biological: Rituximab; Drug: Venetoclax Sponsors: Northwestern University; National Cancer Institute (NCI); Brist...
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
Conditions: Mild Cognitive Impairment; Idiopathic Membranous Nephropathy Interventions: Drug: prednisone,methylprednisone and cyclophosphamide; Drug: Rituximab Sponsors: Beijing Friendship Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Conditions: B-Cell Non-Hodgkin Lymphoma (B-NHL) Interventions: Drug: Odronextamab; Drug: Ifosfamide; Drug: Carboplatin; Drug: Etoposide; Drug: Rituximab; Drug: Dexamethasone; Drug: Cisplatin; Drug: Cytarabine; Drug: Gemcitabine Sponsors: Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Conditions: DLBCL - Diffuse Large B Cell Lymphoma Interventions: Drug: Dexrazoxane; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisolone; Drug: Lenalidomide Sponsors: Stichting Hemato-Oncologie voor Volwassenen Nederland; UMC Utrecht; Amsterdam University Medical Centers; The Dutch Network for Cardiovascular Research (WCN) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma Interventions: Procedur...
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell Interventions: Biological: Liso-cel; Drug: Idelalisib; Drug: Rituximab; Drug: Bendamustine; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Conditions: Hodgkin Lymphoma Interventions: Drug: Brentuximab vedotin; Drug: Rituximab; Drug: Doxorubicin; Drug: Vincristine; Drug: Dacarbazine Sponsors: Beijing Children ' s Hospital Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Conditions: Follicular Lymphoma (FL) Interventions: Drug: Epcoritamab; Drug: Prednisone; Drug: Rituximab; Drug: Lenalidomide; Drug: Doxorubicin; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Obinutuzumab; Drug: Bendamustine Sponsors: AbbVie; Genmab Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
Conditions: Primary Ocular Adnexal MALT Lymphoma Interventions: Drug: Rituximab; Radiation: Involved Site Radiation Therapy Sponsors: Zhongshan Ophthalmic Center, Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin; Child, Only Interventions: Other: intrathecal rituximab Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
